PolyPid (PYPD) Stock Price, News & Analysis

Company Overview

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

Key Stats

• Today's Range: $3.30 to $3.49
• 50-Day Range: $3.20 to $3.65
• 52-Week Range: $2.95 to $9.20
• Volume: 3,477 shs
• Average Volume: 6,473 shs
• Market Capitalization: $16.37 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Buy

PolyPid Stock Analysis - MarketRank™

PolyPid scored higher than 57% of companies evaluated by MarketBeat, and ranked 519th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

PolyPid has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

PolyPid has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for PolyPid are expected to grow in the coming year, from ($4.39) to ($2.21) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of PolyPid is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of PolyPid is -0.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

PolyPid has a P/B Ratio of 7.76. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.46% of the float of PolyPid has been sold short.

Short Interest Ratio / Days to Cover

PolyPid has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in PolyPid has recently increased by 97.44%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

PolyPid does not currently pay a dividend.

Dividend Growth

PolyPid does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.46% of the float of PolyPid has been sold short.

Short Interest Ratio / Days to Cover

PolyPid has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in PolyPid has recently increased by 97.44%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.8 / 5
• News Sentiment: 1.08

News Sentiment

PolyPid has a news sentiment score of 1.08. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for PolyPid this week, compared to 1 article on an average week.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, PolyPid insiders have not sold or bought any company stock.

Percentage Held by Insiders

24.70% of the stock of PolyPid is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 26.47% of the stock of PolyPid is held by institutions.

PYPD Stock Analysis - Frequently Asked Questions

How have PYPD shares performed this year?

PolyPid's stock was trading at $3.80 at the start of the year. Since then, PYPD shares have decreased by 8.2% and is now trading at $3.49.
View the best growth stocks for 2024 here.

How were PolyPid's earnings last quarter?

PolyPid Ltd. (NASDAQ:PYPD) issued its earnings results on Wednesday, November, 10th. The company reported ($15.90) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($19.80) by $3.90.

When did PolyPid's stock split?

PolyPid shares reverse split on the morning of Thursday, September 21st 2023. The 1-30 reverse split was announced on Wednesday, September 20th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

When did PolyPid IPO?

PolyPid (PYPD) raised $50 million in an initial public offering on Friday, June 26th 2020. The company issued 3,100,000 shares at $15.00-$17.00 per share. Barclays and BMO Capital Markets acted as the underwriters for the IPO and Raymond James, National Securities Corporation, Oddo BHF and A.G.P. were co-managers.

Who are PolyPid's major shareholders?

Top institutional shareholders of PolyPid include Rosalind Advisors Inc. (14.16%) and Stonepine Capital Management LLC (2.89%).

How do I buy shares of PolyPid?

Shares of PYPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of PolyPid own?

Based on aggregate information from My MarketBeat watchlists, some other companies that PolyPid investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), Tesla (TSLA), Teladoc Health (TDOC), CrowdStrike (CRWD), PayPal (PYPL) and Roku (ROKU).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 11/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical & medical instruments
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:PYPD
• CUSIP: N/A
• CIK: 1611842
• Web: www.polypid.com
• Phone: 972-74-719-5700
• Fax: N/A
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $12.00
• High Stock Price Target: $14.00
• Low Stock Price Target: $10.00
• Potential Upside/Downside: +243.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($7.81)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-23,860,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -1,219.71%
• Return on Assets: -134.48%

Debt

• Debt-to-Equity Ratio: 1.17
• Current Ratio: 1.00
• Quick Ratio: 1.00

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.27) per share
• Price / Book: -2.75

Miscellaneous

• Outstanding Shares: 4,800,000
• Free Float: 3,612,000
• Market Cap: $16.75 million
• Optionable: No Data
• Beta: 1.31